Price T Rowe Associates Inc Evolus, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Evolus, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 39,882 shares of EOLS stock, worth $425,142. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,882
Previous 38,245
4.28%
Holding current value
$425,142
Previous $403,000
38.71%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EOLS
# of Institutions
173Shares Held
47MCall Options Held
720KPut Options Held
532K-
Perceptive Advisors LLC New York, NY5.75MShares$61.3 Million1.69% of portfolio
-
Tang Capital Management LLC San Diego, CA4.15MShares$44.2 Million7.07% of portfolio
-
Black Rock Inc. New York, NY3.26MShares$34.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$32.4 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.91MShares$31 Million2.62% of portfolio
About Evolus, Inc.
- Ticker EOLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 56,094,800
- Market Cap $598M
- Description
- Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...